Drug Libraray

DCTPepD ID DCTPepD0050

Active Ingredients Balixafortide

Description An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Balixafortide binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.

Synonyms POL6326; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his Cyclic (2->9)-disulfide; Balixafortide

Disease Breast Cancer

Classification

CXCR4 inhibitor Peptide and derivative Cyclic

Molecular Formula C84H118N24O21S2

Molecular Weight 1864.1

Active Sequence Not available

Sequence Length Not available

Modification Not available

Structure

Show IUPAC/InChI/SMILES

IUPAC Name 3-[(1R,4S,7S,10S,16S,22R,25S,28S,31S,34R,37S,40S,43S,46R,52S,55S)-25-(4-aminobutyl)-43-(2-aminoethyl)-40-(3-carbamimidamidopropyl)-55-(hydroxymethyl)-10,31,37-tris[(4-hydroxyphenyl)methyl]-7-(1H-imidazol-5-ylmethyl)-4,52-dimethyl-3,8,11,17,23,26,29,32,35,38,39,42,45,51,54,57-hexadecaoxo-59,60-dithia-2,5,6,9,12,18,24,27,30,33,36,41,44,50,53,56-hexadecazapentacyclo[32.23.4.012,16.018,22.046,50]henhexacontan-28-yl]propanamide

InChI InChI=1S/C84H118N24O21S2/c1-44-70(116)102-62-41-130-131-42-63(77(123)98-57(35-46-14-20-50(110)21-15-46)69(115)68(114)53(10-5-31-91-84(88)89)94-73(119)56(28-30-86)97-79(125)64-11-6-32-106(64)81(127)45(2)93-76(122)61(40-109)101-78(62)124)103-74(120)58(36-47-16-22-51(111)23-17-47)99-72(118)55(26-27-67(87)113)95-71(117)54(9-3-4-29-85)96-80(126)65-12-7-33-107(65)83(129)66-13-8-34-108(66)82(128)60(37-48-18-24-52(112)25-19-48)100-75(121)59(105-104-44)38-49-39-90-43-92-49/h14-25,39,43-45,53-66,104-105,109-112H,3-13,26-38,40-42,85-86H2,1-2H3,(H2,87,113)(H,90,92)(H,93,122)(H,94,119)(H,95,117)(H,96,126)(H,97,125)(H,98,123)(H,99,118)(H,100,121)(H,101,124)(H,102,116)(H,103,120)(H4,88,89,91)/t44-,45-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64+,65+,66-/m0/s1

InChI_Key OYWQJZAVFWOOBF-WBMPNIIXSA-N

SMILES C[C@@H]1NN[C@H](C(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]4CSSC[C@@H](C(N[C@H](C(N[C@H](C(N5CCC[C@@H]5C(N[C@H](C(N[C@H](C(C([C@@H](NC4=O)CC6=CC=C(C=C6)O)=O)=O)CCCNC(N)=N)=O)CCN)=O)=O)C)=O)CO)=O)NC1=O)=O)CC7=CC=C(C=C7)O)=O)CCC(N)=O)=O)CCCCN)=O)=O)=O)CC8=CC=C(C=C8)O)=O)CC9=CN=CN9

PubChem CID 138752609

DrugBank Accession Number DB15370

NCI Thesaurus Code C91094

UNII PRC974M49B GSRS

CAS 1051366-32-5

Drug indication
Investigated for use/treatment in locally recurrent/metastatic/advanced breast cancer.

The drug is not approved.

ClinicalTrials.gov Identifier	Title	Condition or disease	Phase	Purpose
NCT04826016	A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer	Advanced Breast Cancer	Phase 1/2	Treatment
NCT01837095	A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer	Metastatic Breast Cancer	Phase 1	Treatment
NCT01413568	A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies	Acute Myeloid Leukemia in Remission; Adult Acute Lymphoblastic Leukemia in Remission; Chronic Myelogenous Leukemia (CML); Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission; Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM); Myelodysplastic Syndrome (MDS); Myeloproliferative Disorders	Phase 1/2	Treatment
NCT03786094	An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer	Metastatic Breast Cancer; Locally Recurrent Breast Cancer	Phase 3	Treatment
NCT01905475	CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction	Large Reperfused ST-Elevation Myocardial Infarction	Phase 2	Treatment

More clinical information is obtained from ClinicalTrials.gov.